U.S. FDA rejects filing for Celgene MS drug, shares fall 7 percent

(Reuters) - U.S. health regulators have rejected Celgene Corp's application seeking approval of a key multiple sclerosis drug due to insufficient data, the company said on Tuesday, a surprise development that will likely delay the entry of one of Celgene's most important pipeline assets.

from Reuters: Health News http://ift.tt/2F9BsB9